Purchase funded by the Thomas Foundation following FDA marketing authorization of ProSense (R) in low-risk breast cancer and inclusion of cryoablation in proposed medical society guidelines ...

Laparoscopic and percutaneous approaches have similar short-term efficacy in treating renal tumors. Laparoscopic (LAP) and CT-guided percutaneous (PERC) cryoablation for renal tumors result in similar ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...

ORLANDO -- Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial showed. At a mean follow-up of 54.2 ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...

Percutaneous cryoablation may provide a safe and effective treatment option for patients with renal tumors, new findings suggest. David J. Breen, MD, and colleagues from University Hospitals of ...

With cancer cases rising sharply across India, the search for more precise, less invasive and patient-friendly treatments has intensified. From robotic surgery ...

MRI-guided cryoablation debuts in Sydney, offering precise, minimally invasive tumour treatment.

PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...

Pulsed field ablation (PFA) was noninferior to cryoballoon ablation for the incidence of a first recurrence of atrial tachyarrhythmia among patients with symptomatic paroxysmal atrial fibrillation, a ...